$AMGN

Miller Derek sold $1.6M of AMGN

Miller Derek (SVP, Human Resources) sold 3,890 shares of AMGEN INC (AMGN) at $402.54 ($1.57M total) across 2 trades on 2026-08-06.

Original reporting
SEC EDGAR · Miller Derek
Published Aug 7, 2026, 10:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 7, 2026, 10:53 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AMGN
Neutral
medium confidence
Mentioned
$AMGN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AMGNNeutralLow
01

Why it matters

It provides transaction-level details (shares, price, total value, post-sale holdings) but no accompanying company event such as guidance, trial results, or regulatory action.

02

Market read

Traders may note the insider sale for sentiment/positioning, but there is no fundamental catalyst in the disclosure.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without context on total holdings or compensation, signal strength is limited.

Relevance 6/10Novelty 3/10Timing: filed 2026-08-07 after 2026-08-06 insider sale

Background

The article is a SEC Form 4 insider transaction disclosure for Amgen (AMGN).

Company-level read

Ticker impact

$AMGNNeutralMedium confidence
Context

AMGN disclosed an insider open-market sale by SVP Human Resources Miller Derek of 3,890 shares at about $402.54 on 2026-08-06.

Expected impact

Likely minimal near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

Form 4 insider sales are common and the filing provides transaction details without earnings, guidance, or operational changes. The absence of a 10b5-1 plan can raise attention, but the article contains no additional catalyst or company-specific news.

Market effects

No clear sector read-through from a single AMGN insider sale.

None indicated.

None indicated.

Counterpoint

The lack of a 10b5-1 plan could be interpreted by some traders as higher near-term risk, even if the sale size is not clearly material to AMGN’s fundamentals.

Key entities

  • AMGN

    Amgen Inc., the company whose insider transaction was reported.

  • Miller Derek

    SVP, Human Resources at Amgen, reported an open-market sale of shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AMGNHighAI 8/10

Wall Street Falls as Hot US Inflation Fuels Fed Rate Hike Bets

Wall Street indices fell Wednesday after hotter-than-expected US inflation data raised Fed rate hike bets. S&P 500, Nasdaq, and Dow Jones declined. CPI rose 0.6% month-over-month, with annual inflation at 3.7%. Tech shares dropped, while healthcare stocks gained. Treasury yields initially surged but later retreated. Corporate earnings from Bank of America, Morgan Stanley, and BlackRock influenced sentiment.

$AMGNMed

AMGN Maintained by Guggenheim -- Price Target Lowered to $378

Guggenheim maintained a Neutral rating on Amgen (AMGN) but lowered its price target from $388 to $378. Amgen's stock is currently trading at $417.57, which is 13.4% above its GF Value™ of $368.11, indicating overvaluation. The company has a GF Score™ of 85/100, showing strong financial health and profitability. Insider activity shows significant selling in the last three months.

$AMGNMed

AMGN Maintained by RBC Capital -- Price Target Raised to $430

RBC Capital maintained an Outperform rating on Amgen (AMGN) and raised its price target to $430 from $400, citing strong growth potential. Amgen's stock is currently trading at $402.06, which is 9.3% above its GF Value™ of $367.93, indicating overvaluation. The company has a GF Score™ of 85/100, reflecting strong profitability and growth but weaker momentum. Insider activity shows significant selling, with $4.1 million in sales over the past three months.

$AMGNMed

Truist raises Amgen stock price target to $380 on pipeline growth

Truist Securities raised its price target for Amgen (AMGN) to $380, citing pipeline growth and revenue projections above consensus. The stock trades at $409.77, with a Fair Value estimate of $447.80. Amgen's Q3 2026 revenue is projected at $10.23B, with non-GAAP EPS of $5.90. Recent trial data for dazodalibep showed positive results, leading to varied analyst price targets.